Truway Health, Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

3 drugs in development

Phase 22

Phase 12

By Therapeutic Area

top 0

No TA breakdown available.

R&D Momentum

62/100

Pipeline Velocity

41/100

Trial Completion Rate

N/A

Pipeline Concentration

100/100

Pipeline Freshness

96/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners

Activity

Recent Activity

Last 14 days

Sep 15, 2026

Enrolling by invitation

Multimodal Physiologic Signal Fusion for 72-Hour Prediction of Acute Clinical Deterioration

Sep 11, 2026

Enrolling by invitation

Prospective Evaluation of Temporal Clinical Dynamics, Physiologic Trajectories, and Time-Dependent Digital Biomarkers for Prediction of Clinically Meaningful Patient Outcomes

Sep 11, 2026

Enrolling by invitation

OMNIPHYS: A Prospective Multimodal Longitudinal Study of AI-Enabled Physiologic State Modeling and Early Detection of Clinical Deterioration

Earlier

Sep 5, 2026TrialProspective Development and External Validation of a Multimodal Whole-Body Digital Twin for Quantification of Cross-Organ Physiologic Reserve, Recovery Dynamics, and Emerging Health-State Change

Sep 3, 2026TrialA Prospective Multicenter Clinical-Performance Study of Federated Machine Learning for Automated Interpretation of Point-of-Care Cardiac Ultrasound

Sep 2, 2026TrialA Prospective Randomized Controlled Study Comparing Ultrasound-Guided Peripheral Vascular Access With Standard Landmark/Palpation-Guided Access for Improving First-Attempt Cannulation Success

Aug 29, 2026TrialProspective Observational Evaluation of Procurement Reliability, Distribution Restrictions, Supply-Chain Disruptions, and Clinical Access to Intracardiac Echocardiography Catheters

Aug 26, 2026TrialNeuroFinance Human Stress Trial During Financial and Informational Volatility (NFHST)

4 more events

Jul 1, 2026TrialA Multiphase Operational and Environmental Assessment of Lunar Surface Habitation, Lunar Gateway Transit Systems, and Acceleration Pathways for Sustained Human Habitation of the Martian Surface

Mar 8, 2026TrialRegenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss

Oct 23, 2025TrialQuantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

Oct 13, 2025TrialHealthcare Integrity & Anti-Fraud Enforcement

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Unknown / Other

CAR

Standard Oral Hypoglycemic Agent

Sensorineural Hearing Loss

Stem Cell Dip

Tics

Skin Cell Dip Stem Cell Dip

Unknown / Other

CAR

Standard Oral Hypoglycemic AgentPhase 1

Sensorineural Hearing Loss

Stem Cell DipPhase 1

Tics

Skin Cell DipPhase 2

Stem Cell DipPhase 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)